The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis
Surgery Today · 2025
DOI: 10.1007/s00595-024-02900-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, 2025. Verfasst von Kai Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Unresectable recurrence is a critical predictor of outcomes for colorectal cancer patients. We attempted to identify the prognostic factors, especially for unresectable recurrence-free survival (URFS) as a new endpoint, in patients with resectable colorectal liver-only metastasis (CRLOM). METHODS: We investigated patients with resectable CRLOM, who underwent an R0 resection for both CRC and CRLOM between January, 2014 and March, 2019 at a single institution. The exclusion criteria were patients who received neoadjuvant treatment, the absence of data for genetic analyses, and the presence of multiple cancers, synchronous CRC, or familial adenomatous polyposis. The prognostic factors were examined retrospectively using data on pre-hepatectomy factors, including primary tumor molecular profiling results. RESULTS: We analyzed the data of 101 patients who underwent curative-intent surgery for CRLOM. Multivariate analysis revealed that KRAS G12D mutation-positivity (hazard ratio [HR]: 7.69; p 37 U/ml before hepatectomy (HR: 3.62; p < 0.01), and primary tumor pN2 stage (HR: 3.22; p = 0.03) were significant predictors of the URFS. CONCLUSIONS: This is the first study to show that specific KRAS and RYR2 mutations were associated with the URFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Colon and Rectal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.
- Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan. okamura.yukiyasu@nihon-u.ac.jp.
- Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. okamura.yukiyasu@nihon-u.ac.jp.
- Cancer Multiomics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
- Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Zitieren
APA
Chen, K., Okamura, Y., Hatakeyama, K., Shiomi, A., Kagawa, H., Hino, H., Manabe, S., Yamaoka, Y., Sugiura, T., Sugino, T., Notsu, A., Nagashima, T., Ohshima, K., Urakami, K., Akiyama, Y., & Yamaguchi, K. (2025). The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis. Surgery Today. https://doi.org/10.1007/s00595-024-02900-3
Vancouver
Chen K, Okamura Y, Hatakeyama K, Shiomi A, Kagawa H, Hino H, et al. The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis. Surgery Today. 2025. doi:10.1007/s00595-024-02900-3
BibTeX
@article{Chen2025,
author = {Chen, Kai and Okamura, Yukiyasu and Hatakeyama, Keiichi and Shiomi, Akio and Kagawa, Hiroyasu and Hino, Hitoshi and Manabe, Shoichi and Yamaoka, Yusuke and Sugiura, Teiichi and Sugino, Takashi and Notsu, Akifumi and Nagashima, Takeshi and Ohshima, Keiichi and Urakami, Kenichi and Akiyama, Yasuto and Yamaguchi, Ken},
title = {The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis},
journal = {Surgery Today},
year = {2025},
doi = {10.1007/s00595-024-02900-3}
}
EUVIMED